Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00063128 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes Mellitus.
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 119
- Enrollment target
NCT00063128 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 119 participants.
The verdict
NCT00063128, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 119 participants
- Enrollment target
Study Summary
This is a research study of a study drug known as LY041001 or human insulin inhalation powder (HIIP). HIIP is a powder form of insulin made to be inhaled through the mouth and into the lungs using a special handheld device.
Interventions
- DRUG insulin
- DRUG human insulin inhalation powder (HIIP)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2003-04 |
| Est. Completion | 2004-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00063128
The ClinicalTrials.gov registry entry for NCT00063128 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 119 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which insulin is the first listed.
NCT00063128 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00063128 about?
NCT00063128 is a clinical study titled "Safety and Efficacy of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes Mellitus.". This is a research study of a study drug known as LY041001 or human insulin inhalation powder (HIIP). HIIP is a powder form of insulin made to be inhaled through the mouth and into the lungs using a special handheld device.
What is the current status of trial NCT00063128?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 119 participants. The study started on 2003-04. Estimated completion is 2004-04.
What interventions are being tested in trial NCT00063128?
The interventions under investigation include: insulin (DRUG), human insulin inhalation powder (HIIP) (DRUG).
Who is sponsoring clinical trial NCT00063128?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.